Key Roles of Hyaluronan and Its CD44 Receptor in the Stemness and Survival of Cancer Stem Cells by Theerawut Chanmee et al.
August 2015 | Volume 5 | Article 1801
Review
published: 10 August 2015
doi: 10.3389/fonc.2015.00180
Frontiers in Oncology | www.frontiersin.org
Edited by: 
Rajeev K. Boregowda, 
Rutgers Cancer Institute of 
New Jersey, USA
Reviewed by: 
Stephan Von Gunten, 
University of Bern, Switzerland 
Barbara Zavan, 
University of Padova, Italy
*Correspondence:
 Naoki Itano, 
Department of Molecular 
Biosciences, Faculty of Life Sciences, 
Kyoto Sangyo University, Kita-ku, 
Kyoto 603-8555, Japan 
itanon@cc.kyoto-su.ac.jp
Specialty section: 
This article was submitted to 
Molecular and Cellular Oncology, 
a section of the 
journal Frontiers in Oncology
Received: 27 April 2015
Accepted: 21 July 2015
Published: 10 August 2015
Citation: 
Chanmee T, Ontong P, Kimata K and 
Itano N (2015) Key roles of 
hyaluronan and its CD44 receptor in 
the stemness and survival of 
cancer stem cells. 
Front. Oncol. 5:180. 
doi: 10.3389/fonc.2015.00180
Key roles of hyaluronan and its CD44 
receptor in the stemness and survival 
of cancer stem cells
Theerawut Chanmee 1, Pawared Ontong 2, Koji Kimata 3 and Naoki Itano 1,2,4*
1 Department of Molecular Biosciences, Faculty of Life Sciences, Kyoto Sangyo University, Kyoto, Japan, 2 Biotechnology, 
Division of Engineering, Graduate School of Engineering, Kyoto Sangyo University, Kyoto, Japan, 3 Research Complex for 
Medical Frontiers, Aichi Medical University, Nagakute, Japan, 4 Institute of Advanced Technology, Kyoto Sangyo University, 
Kyoto, Japan
Cancer stem cells (CSCs) represent a unique subpopulation of self-renewing oncogenic 
cells that drive cancer initiation and progression. CSCs often acquire multidrug and 
oxidative stress resistance and are thereby thought to be responsible for tumor recur-
rence following treatment and remission. Although the mechanisms responsible for CSC 
generation, maintenance, and expansion have become a major focus in cancer research, 
the molecular characteristics of CSCs remain poorly understood. The stemness and 
subsequent expansion of CSCs are believed to be highly influenced by changes in micro-
environmental signals as well as genetic and epigenetic alterations. Hyaluronan (HA), a 
major component of the extracellular matrix, has recently been demonstrated to provide 
a favorable microenvironment for the self-renewal and maintenance of stem cells. HA 
directly and indirectly affects CSC self-renewal by influencing the behavior of both cancer 
and stromal cells. For instance, HA in the tumor microenvironment modulates the function 
of tumor-associated macrophages to support CSC self-renewal, and excessive HA pro-
duction promotes the acquisition of CSC signatures through epithelial-to-mesenchymal 
transition. The importance of HA in mediating CSC self-renewal has been strengthened by 
the finding that interactions between HA and its receptor, CD44, propagate the stemness 
of CSCs. HA–CD44 interactions evoke a wide range of signals required for CSC self-re-
newal and maintenance. CD44 also plays a critical role in the preservation and multidrug 
resistance (MDR) of CSCs by transmitting survival and anti-apoptotic signals. Thus, a bet-
ter understanding of the molecular mechanisms involved in HA and CD44 control of CSC 
stemness may help in the design of more effective therapies for cancer patients. In this 
review, we address the key roles of HA and CD44 in CSC self-renewal and maintenance. 
We also discuss the involvement of CD44 in the oxidative stress and MDR of CSCs.
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introduction
Cancer stem cells (CSCs) are a subpopulation of oncogenic cells that have an ability to self-renew 
and the potential for generating heterogeneous malignant progenies (1, 2). CSCs are thought to 
be responsible for cancer initiation, progression, and metastasis. Furthermore, they can acquire 
resistance to chemotherapy and oxidative stress. The CSC hypothesis has therefore garnered much 
August 2015 | Volume 5 | Article 1802
Chanmee et al. HA and CD44 promote cancer stemness
Frontiers in Oncology | www.frontiersin.org
attention due to the high-therapeutic potential of CSC-targeting 
treatments. Recently, a great amount of effort has been invested 
on identifying CSCs in various types of cancers and the key 
molecules involved in controlling the unique properties of 
CSC populations. Putative markers specific for CSCs have been 
discovered and enable us to distinguish CSCs from normal stem 
cells and non-stem cancer cells (Table 1). Although there is still 
debate on the origin of CSCs, several prominent studies have 
contributed important insights on the generation of these cells. 
CSCs might appear after sequential mutations in specific stem 
cells or early cell progenitors. Phenotypic plasticity has also been 
demonstrated to allow cancer cells to dynamically enter into a 
stem-cell state (3). Furthermore, emerging evidence has sug-
gested that cancer cells undergoing epithelial-to-mesenchymal 
transition (EMT) acquire stem-like cell signatures, such as the 
ability of self-renewal (4). The stemness properties and subse-
quent expansion of CSCs are highly influenced by microenviron-
mental signals as well as genetic and epigenetic regulation (5, 6). 
Among such microenvironmental molecules, hyaluronan (HA) 
has recently been shown to maintain the stemness of normal 
stem cells. HA could also promote the acquisition of CSC signa-
tures through EMT and support CSC self-renewal by modulating 
the function of stromal cells. CD44 is a known HA receptor and 
prominent marker of CSCs in several types of cancer (7–9). 
Early observations have demonstrated a significant correlation 
between CD44 and tumor mortality (10), and growing evidence 
has suggested that CD44 is not only a CSC marker but also a 
mediator of many functional roles of CSCs. Collectively, both 
HA and CD44 appear to be strongly linked to the generation, 
maintenance, and survival of CSCs. This review focuses on the 
key roles of HA and CD44 in the regulation of CSC stemness and 
sustainability.
HA and its CD44 Receptor
HA is a linear polysaccharide that belongs to the glycosamino-
glycan family. It is composed of repeating disaccharide units of 
glucuronic acid and N-acetylglucosamine (Figure 1A) and has a 
molecular mass ranging from 103 to 107 Da, depending on tissue 
TABLe 1 | Cell surface markers of cancer stem cells.
CSC marker(s) Cancer type Reference
CD44+ Head and neck, gastric, lung (11–13)
CD44+CD24+ Head and neck (14)
CD44+CD24− Breast (15, 16)
CD44+CD24+ESA+ Pancreatic (17)
CD44v3highALDH1 Head and neck (18)
CD44+α2β1highCD133+ Prostate (9)
CD44+EpCAMhigh Colorectal (8)
CD44+CK5+CK20− Bladder (19)
CD44+CD117+ Ovarian (20)
CD44+CD90+ Lung, liver (21, 22)
CD34+CD38− Acute myeloid leukemia, acute 
lymphoid leukemia
(23)
CD133 Brain, colon, ovary, lung, melanoma (24–28)
ABCB5+ Melanoma (29)
type and physiological condition. HA is ubiquitously found in 
the extracellular matrix (ECM) of vertebrate tissues and is known 
to contribute to cell proliferation, migration, and adhesion (30). 
A wide variety of HA-binding molecules also participate in the 
assembly of pericellular HA–ECM to regulate HA function. 
Despite its relatively simple chemical composition, HA mediates 
many important processes during embryonic morphogenesis, 
tissue regeneration, and wound healing (31). Abnormalities in 
HA metabolism have been implicated in numerous conditions, 
including inflammatory disorders, cardiovascular diseases, and 
cancer. The biosynthesis and degradation processes of HA are 
tightly regulated by three HA synthases (HAS1–3) and several 
hyaluronidases, respectively. HAS possesses a glycosyltrans-
ferase ability that catalyzes the polymerization of glucuronic 
acid and N-acetylglucosamine to the nascent HA chain. Each 
HAS isoform exhibits different enzymatic properties with regard 
to stability, enzyme kinetics, and rate of chain elongation (32).
CD44 is a transmembrane glycoprotein known to act as a 
receptor for a wide variety of ECM ligands, such as HA, col-
lagen, fibronectin, laminin, osteopontin, and heparin-binding 
epidermal growth factor (HB-EGF). Structurally, CD44 proteins 
contain an N-terminal HA-binding link-homology module, 
stem region, transmembrane domain, and short C-terminal 
cytoplasmic domain (Figure  1B). The receptor binds to its 
major physiologic ligand, HA, via the N-terminal HA-binding 
link-homology module. CD44 can exerts an intracellular signal-
ing by associated with its ligand or modifying the function of 
growth factor receptors and thereby affected to the downstream 
signaling molecules through the cytoplasmic tail. The CD44 
cytoplasmic tail can form complex with many cytoskeletal 
proteins and intracellular signaling components, such as Rho-
family GTPases, Src family kinases, and associated molecules that 
affected to cell adhesion and migration (33). The active and inac-
tive states of CD44 are multiply regulated by dimerization and 
post-translational modification, such as N- and O-glycosylation, 
under appropriate circumstances (34, 35). CD44 is encoded by a 
single gene containing 20 exons. The standard isoform (CD44s) 
is encoded by constant exons 1–5 and 16–20 and translated into 
a polypeptide of a molecular mass of 80–85  kDa. The variable 
exons 6–15 (v1–v10) are regulated by alternative splicing to 
generate multiple variant isoforms (Figure 1C) that are expressed 
in tissue- and stage-specific manners during both embryonic 
development and carcinogenesis (36). Most notably, CD44 is a 
common marker of CSCs in several types of human carcinoma, 
including cancers of the breast, prostate, bladder, colon, ovary, 
stomach, cervix, uterus, nasopharynx, head and neck, lung, and 
pancreas (Table 1).
impact of HA and CD44 on Cancer 
Progression
Elevated levels of HA are found in many types of human cancer, 
and HA accumulation within tumor stroma has been shown to 
be closely correlated with poor prognosis and survival in cancer 
patients (37–39). Clinicopathological studies have indicated 
that the high HA levels in the peri- and intratumoral stroma 
FiGURe 1 | Schematic diagram of HA and CD44 structures. (A) HA is a 
linear polysaccharide composed of repeating disaccharide units of glucuronic 
acid and N-acetylglucosamine. (B) The CD44 protein consists of an N-terminal 
HA-binding link-homology module, stem region, transmembrane domain, and 
short C-terminal cytoplasmic domain. (C) CD44 is encoded by 20 exons, 
among which exons 1–5 and 16–18 are constant regions contained in all CD44 
isoforms. Exon 19 encodes an alternatively spliced short form that spliced out 
in most CD44 isoforms. Exons 6–15 are variant exons, typically identified as 
vl–v10, which can be alternatively spliced and give rise to multiple variant 
CD44. In human, exon 6 (exon v1) encodes a stop codon and is not 
expressed. CD44 variant can contain one or more variant regions, such as 
CD44v3, CD44v3–10, CD44v4–10, or CD44v8–10.
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type and physiological condition. HA is ubiquitously found in 
the extracellular matrix (ECM) of vertebrate tissues and is known 
to contribute to cell proliferation, migration, and adhesion (30). 
A wide variety of HA-binding molecules also participate in the 
assembly of pericellular HA–ECM to regulate HA function. 
Despite its relatively simple chemical composition, HA mediates 
many important processes during embryonic morphogenesis, 
tissue regeneration, and wound healing (31). Abnormalities in 
HA metabolism have been implicated in numerous conditions, 
including inflammatory disorders, cardiovascular diseases, and 
cancer. The biosynthesis and degradation processes of HA are 
tightly regulated by three HA synthases (HAS1–3) and several 
hyaluronidases, respectively. HAS possesses a glycosyltrans-
ferase ability that catalyzes the polymerization of glucuronic 
acid and N-acetylglucosamine to the nascent HA chain. Each 
HAS isoform exhibits different enzymatic properties with regard 
to stability, enzyme kinetics, and rate of chain elongation (32).
CD44 is a transmembrane glycoprotein known to act as a 
receptor for a wide variety of ECM ligands, such as HA, col-
lagen, fibronectin, laminin, osteopontin, and heparin-binding 
epidermal growth factor (HB-EGF). Structurally, CD44 proteins 
contain an N-terminal HA-binding link-homology module, 
stem region, transmembrane domain, and short C-terminal 
cytoplasmic domain (Figure  1B). The receptor binds to its 
major physiologic ligand, HA, via the N-terminal HA-binding 
link-homology module. CD44 can exerts an intracellular signal-
ing by associated with its ligand or modifying the function of 
growth factor receptors and thereby affected to the downstream 
signaling molecules through the cytoplasmic tail. The CD44 
cytoplasmic tail can form complex with many cytoskeletal 
proteins and intracellular signaling components, such as Rho-
family GTPases, Src family kinases, and associated molecules that 
affected to cell adhesion and migration (33). The active and inac-
tive states of CD44 are multiply regulated by dimerization and 
post-translational modification, such as N- and O-glycosylation, 
under appropriate circumstances (34, 35). CD44 is encoded by a 
single gene containing 20 exons. The standard isoform (CD44s) 
is encoded by constant exons 1–5 and 16–20 and translated into 
a polypeptide of a molecular mass of 80–85  kDa. The variable 
exons 6–15 (v1–v10) are regulated by alternative splicing to 
generate multiple variant isoforms (Figure 1C) that are expressed 
in tissue- and stage-specific manners during both embryonic 
development and carcinogenesis (36). Most notably, CD44 is a 
common marker of CSCs in several types of human carcinoma, 
including cancers of the breast, prostate, bladder, colon, ovary, 
stomach, cervix, uterus, nasopharynx, head and neck, lung, and 
pancreas (Table 1).
impact of HA and CD44 on Cancer 
Progression
Elevated levels of HA are found in many types of human cancer, 
and HA accumulation within tumor stroma has been shown to 
be closely correlated with poor prognosis and survival in cancer 
patients (37–39). Clinicopathological studies have indicated 
that the high HA levels in the peri- and intratumoral stroma 
FiGURe 1 | Schematic diagram of HA and CD44 structures. (A) HA is a 
linear polysaccharide composed of repeating disaccharide units of glucuronic 
acid and N-acetylglucosamine. (B) The CD44 protein consists of an N-terminal 
HA-binding link-homology module, stem region, transmembrane domain, and 
short C-terminal cytoplasmic domain. (C) CD44 is encoded by 20 exons, 
among which exons 1–5 and 16–18 are constant regions contained in all CD44 
isoforms. Exon 19 encodes an alternatively spliced short form that spliced out 
in most CD44 isoforms. Exons 6–15 are variant exons, typically identified as 
vl–v10, which can be alternatively spliced and give rise to multiple variant 
CD44. In human, exon 6 (exon v1) encodes a stop codon and is not 
expressed. CD44 variant can contain one or more variant regions, such as 
CD44v3, CD44v3–10, CD44v4–10, or CD44v8–10.
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of epithelial ovarian cancer were significantly associated with 
poor differentiation, progressed histological type, and advanced 
stage (37). High stromal HA was also strongly related to reduced 
overall and disease-free survival and was more frequently 
observed in metastatic lesions than in primary tumors (38). 
HAS overexpression has similarly been implicated in cancer 
progression (40). In human breast cancer, localization and 
elevated expression of HAS were correlated with prognostic 
factors and patient outcome (41). Specifically, HAS1 expression 
in breast carcinoma cells associated with a high relapse rate and 
short overall survival, while expression levels of stromal HAS1 
and HAS2 were positively related to tumor size and lymph node 
metastasis (41). Elevated HAS2 expression was also witnessed 
in highly invasive breast carcinoma cells (42). Experimental 
evidence has highlighted the functional roles of HA in tumor 
growth and metastasis. For instance, our previous study demon-
strated that mutant mammary carcinoma cells lacking the ability 
to synthesize HA displayed a significant decrease in metastatic 
ability in an experimental model of lung metastasis, which was 
restored by the re-establishment of HA synthesis by HAS1 trans-
fection in accordance with formation of an HA-rich pericellular 
coat (43). Kosaki et al. genetically manipulated HA production 
by HAS2 transfection in a human HT1080 fibrosarcoma cell 
line and observed the enhancement of anchorage-independent 
growth and tumorigenicity (44). Similarly, forced expression 
of HAS3 promoted the tumorigenic ability of melanoma cells 
by accelerating tumor angiogenesis (45), but suppression of 
HAS2 or HAS3 inhibited the initiation and progression of 
primary and secondary tumor formation in  vivo (46). Thus, 
HA appears to be a crucial factor in determining the malignant 
characteristics of cancers. The functional importance of HA in 
tumor progression was also demonstrated in our recent study 
using an HA-overproducing breast cancer model in Has2 trans-
genic mice. We found that HA overproduction in cancer cells 
promoted tumor progression by accelerating angiogenesis and 
lymphangiogenesis concurrently with the formation of stromal 
structures (40, 47).
The HA-rich tumor microenvironment contributes promi-
nently to tumor neovascularization by enhancing the recruit-
ment of host stromal cells, such as fibroblasts, monocytes/
macrophages, endothelial cells, and mesenchymal stem cells. The 
pericellular HA matrix with cable-like structure was reported to 
facilitate monocyte/macrophage recruitment in vascular lesions 
via CD44 (48), which, in turn, released pro-angiogenic factors 
essential for tumor angiogenesis (49). Notably, macrophages 
were seen to preferentially traffic to HA-enriched stromal 
structures in spontaneous mammary tumors (47). Depletion of 
macrophages reduced both tumor angiogenesis and lymphangi-
ogenesis in HA-producing tumors, and disruption of the Has2 
gene in tumor-associated fibroblasts (TAFs) led to impairment 
of macrophage infiltration following inoculation of mammary 
carcinoma cells into nude mice. Concurrently with diminished 
macrophage recruitment,  Has2-null TAFs attenuated tumor 
angiogenesis and lymphangiogenesis. These findings strongly 
suggest that stromal HA promotes tumor neovascularization 
via the preferential engagement of tumor-associated mac-
rophages (TAMs).
HA is typically present in normal tissues as high-molecular 
weight HA (HMW-HA) with an average molecular weight of 
approximately 107 Da. The appearance of its lower molecular 
weight could influence cell behavior. Significant amounts 
of HA fragments have been detected in malignant tumors, 
for which increases correlated with tumor aggressiveness in 
humans (50–52). The properties and functions of HA appear 
to depend on molecular size; HA oligosaccharides of 4–25 
disaccharide units exhibited pro-angiogenic capabilities by 
enhancing the proliferation and migration of endothelial 
cells, while HMW–HA was observed to function as an anti-
angiogenic agent (53, 54). Dependent on polymer length, 
HA can also exist as both a pro- and an anti-inflammatory 
molecule in  vivo (55, 56). These contradictory functions 
of HA in angiogenic and inflammatory processes are regu-
lated by a complex interplay between HA production and 
degradation.
Interactions between HA and CD44 have been shown to 
play essential roles in tumor cell growth, survival, migration, 
and metastasis. Inhibition of HA–CD44 binding by HA oli-
gosaccharides led to suppression of tumor cell growth in vivo 
by disruption of the phosphoinositide 3-kinase (PI3K)/Akt 
survival pathway (57). Knockdown of CD44 decreased the 
adhesiveness of human colon cancer cells to HA, cancer colony-
forming ability in soft agar assays, and xenograft tumorigenicity, 
while increasing susceptibility to etoposide-induced apoptosis 
(58). CD44 expression also correlated with tumor recurrence 
after surgical treatment (59–61). Activation of CD44 has been 
seen to promote multidrug resistance (MDR) in cancer cells, 
which is a hallmark of therapeutic resistance. Not surprisingly, 
neutralizing antibodies targeting CD44 effectively inhibited 
tumor growth and prevented tumor relapse after chemotherapy-
induced remission in an orthotopic xenograft model of human 
breast cancer (62).
Expression of CD44 variant proteins has also been implicated 
in tumor progression (63). The CD44v3 isoform was observed 
to play a role in the progression of head and neck squamous cell 
carcinoma (HNSCC) by stimulating cell growth, migration, and 
metalloproteinase (MMP) expression (64). Transfection of this 
isoform into an HNSCC cell line markedly increased tumor cell 
migration (64). Moreover, overexpression of specific CD44 vari-
ants in non-metastasizing pancreatic carcinoma and mammary 
adenocarcinoma cell lines led to metastatic behavior (65). All of 
these findings highlight the important roles of CD44 in cancer 
progression and recurrence.
HA and eMT
A close link between EMT and CSC properties has emerged to 
enable a greater understanding of the molecular mechanisms 
underlying the expansion and maintenance of CSCs in tumor 
masses. Increasing evidence suggests that HA plays a central 
role in EMT during embryonic development and malignant 
progression. Zoltan-Jones et al. demonstrated that forced HAS2 
expression induced Madin–Darby canine kidney and MCF-10A 
human mammary epithelial cells to acquire mesenchymal-like 
phenotype as defined by a down-regulation of E-cadherin 
FiGURe 2 | involvement of HA in the induction of eMT and CSC 
self-renewal. An alternative mechanism of HA–CD44 interaction-promoted 
EMT relying on activation of the lysyl oxidase promoter leads to the up-
regulation of Twist. HA overproduction also induces EMT through the 
coordinated regulation of Twist and TGF-β-Snail signaling. In addition, TGF-β 
facilitates EMT by increasing the expression of HAS2. This stimulatory effect 
requires the activation of Smad and p38 MAPK. CD44 maintains the 
self-renewal ability of CSCs through Nanog and GSK3β. HA and CD44 
promote Nanog protein association with CD44 followed by activation of the 
stem-cell regulators Rex1 and Sox2. CD44 also inhibits the phosphorylation of 
GSK3β to maintain the functional indicators of cancer stemness, including EMT 
and stem-cell markers (e.g., Oct4, Sox2, and Nanog).
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at intercellular boundaries, up-regulation of vimentin, and 
fibroblast-like morphology (66). Ectopic expression of murine 
Has2 in non-HA-producing mesothelioma cells also invoked 
conversion to fibroblastic morphology (67). In  vivo experi-
ments have confirmed the importance of HA in the induction 
of EMT. Disruption of the Has2 gene abrogated normal cardiac 
morphogenesis and HA-mediated transformation of epithelium 
to mesenchyme (68). We produced conditional transgenic 
mice carrying the murine Has2 gene and observed that HA 
overproduction in spontaneous mammary tumors resulted in a 
loss of epithelial phenotype in tumor cells by down-regulation 
of E-cadherin and induced nuclear translocation of β-catenin, 
both of which are hallmarks of EMT (40). Transcriptional 
networks that drive EMT (e.g., Snail, Twist, and Zeb1) have 
also been found to dynamically change during HA-induced 
EMT. We witnessed that HA overproduction up-regulated Snail 
and Twist expression in a mammary carcinoma cell (Figure 2) 
(69). Furthermore, HA association with CD44 was suggested to 
induce Twist expression following CD44 nuclear translocation 
and activation of the lysyl oxidase promoter in human breast 
cancer (Figure 2) (70).
During malignancy progression, activated fibroblasts, immune 
cells, and other stromal cells infiltrate into tumors and construct 
tumor microenvironments through secretion of cytokines and 
growth factors. The EMT program in tumor cells is extensively 
regulated by networks of such mediators. Several studies sup-
port the functional role of autocrine/paracrine cytokine loops 
in controlling HA-induced EMT. TGF-β, a known potent EMT 
inducer that is abundantly secreted by both stromal and tumor 
cells, has been shown to induce Twist, Snail, and Zeb1 in many 
types of cancers. Porsch et al. demonstrated that the regulatory 
mechanisms of TGF-β-induced EMT required HAS2 expres-
sion in mammary epithelial cells (Figure 2). Silencing of HAS2 
suppressed TGF-β-induced EMT as evidenced by a reduction 
in the EMT markers, such as fibronectin, Snail, and Zeb1 (71). 
The release of hepatocyte growth factor (HGF) by stromal cells 
can also contribute to EMT induction. HGF promoted EMT-
like phenotype in hepatocellular carcinoma cells through the 
down-regulation of E-cadherin and up-regulation of Snail and 
N-cadherin (72). Zoltan-Jones et  al. showed that elevated HA 
production evoked mesenchymal and transformed properties in 
epithelial cells via the transforming activities of HGF (66).
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Roles of HA and CD44 in CSC  
Self-Renewal and Maintenance
Stem cells reside in a special microenvironmental niche that 
provides the major cues for promoting survival and maintenance, 
and HA is a primary ECM component of this stem-cell niche. A 
recent study indicated that human bone marrow mesenchymal 
stem cells synthesized a large amount of HA to retain their 
pericellular coats and maintain their stemness (73). Like in a 
normal stem-cell niche, HA-rich ECM provides a favorable 
microenvironment for self-renewal and maintenance of CSCs. 
HA in the tumor microenvironment also indirectly affects CSC 
self-renewal by influencing the behavior of stromal cells. Okuda 
et al. reported that HA produced by metastatic breast cancers pro-
moted the interactions between TAMs and CSCs that preceded 
platelet-derived growth factor (PDGF)-BB secretion from TAMs. 
PDGF-BB then activated fibroblasts and osteoblasts to support 
CSC self-renewal through the induction of fibroblast growth 
factor (FGF)-7 and FGF-9 expression (74).
Gene expression profiles in cancer cells have suggested an 
important molecular link between EMT and cancer stemness. 
Tumor cells undergoing EMT often acquire stem-like cell profiles, 
such as self-renewing ability. Overexpression of the EMT-related 
transcription factors, Snail and Twist, induced mesenchymal 
traits in breast cancer cells and generated subpopulations with a 
CD44highCD24low phenotype that have been observed in human 
breast CSCs (4, 15). Considerable evidence supporting the key 
role of HA in EMT induction has surfaced in recent years from 
cell and animal studies. Forced expression of Has2 resulted in the 
loss of epithelial phenotype in mammary epithelial cells (66). Our 
in vivo study with a conditional transgenic mouse model allow-
ing Has2 overexpression in breast cancer demonstrated that HA 
overproduction caused rapid development of aggressive breast 
carcinoma at a high incidence (40). In the HA-rich carcinoma 
mass, the cancer cells had acquired an EMT phenotype as defined 
by the down-regulation of E-cadherin and increased nuclear 
translocation of β-catenin. Interestingly, HA-overproducing 
tumor cells acquired stemness via the up-regulation of TGF-β and 
induction of Snail and Twist, while a loss of EMT by inhibition 
of TGF-β-Snail signaling or Twist knockdown markedly reduced 
CSC subpopulations (69). Thus, HA appears to play a crucial role 
in the acquisition of CSC signatures by promoting EMT.
Several studies have recently highlighted the essentiality 
of CD44 in CSC self-renewal and maintenance. In HNSCC, 
ALDHhigh/CD44high cells exhibited similar self-renewal and 
tumor-initiating properties as CSCs through the suppression of 
BMP signaling (75). Although its precise mechanism remains 
undefined, CD44 may act as an intracellular scaffold protein for 
Smad1, and their interactions may potentiate the long-term sur-
vival of CSCs by regulating BMP/Smad signaling (76). Shigeishi 
et al. have demonstrated that CD44-mediated GSK3β activation 
is required for the maintenance of CSC properties, whereby 
CSCs undergoing EMT are dependent on GSK3β activity for 
mesenchymal phenotype (Figure 2) (77). CD44 knockdown in 
CSCs resulted in inactivation of GSK3β, induction of epithelial 
phenotype, and a significant decrease in the number of tumor 
spheres.
Stem-cell-specific transcription factors (e.g., Sox2, Klf4, Oct4, 
and Nanog) are frequently encountered in human cancers, and 
their transcriptional networks are necessary for the development 
and maintenance of cancer stem-like cells (78–80). Interactions 
between HA and CD44v3 propagated CSC stemness through 
formation of complexes containing the cell-specific transcription 
factors Oct4, Sox2, and Nanog in human HNSCC (18). Complex 
formation stimulated microRNA-302 (miR302) expression 
and led to the suppression of the epigenetic regulators AOF1/
AOF2/DNMT1 and up-regulation of several survival proteins 
(Figure 3) (18). In addition, HA/CD44-mediated Nanog activa-
tion promoted the expression of the stem-cell regulators, such as 
Rex1 and Sox2 (Figure 2), whereas CD44 knockdown attenuated 
the expression of stem-cell markers, including Oct4, Nanog, and 
Sox2 (77). These lines of evidence emphasize that HA and CD44 
are indispensable factors in CSC self-renewal, clonal formation, 
and chemotherapy resistance (81).
Survival and Anti-Apoptotic Signals 
Generated by HA–CD44 interactions
CD44 plays a key role in the continuity of many tumor cells 
by transmitting survival and anti-apoptotic signals. CD44 and 
receptor tyrosine kinases (RTKs) have been shown to promote 
cell survival in a cooperative fashion. HA–CD44 interactions 
trigger activation of CD44-associated Src, ezrin phosphoryla-
tion, and PI3K activation. This signaling cascade subsequently 
up-regulates the assembly of protein complexes, such as heat 
shock protein 70 and the co-chaperone CDC37, leading to 
the phosphorylation and activation of ERBB2/ERBB3 RTKs 
(82). Besides the induction of survival signals, CD44–RTK 
cooperation conferred apoptosis resistance via stimulation of 
cyclooxygenase 2 expression followed by the production of 
prostaglandin E2 (83). CD44 also prevents apoptosis through 
molecular alterations in pro- and anti-apoptotic factors. 
Lakshman et  al. demonstrated that the acquisition of resist-
ance to etoposide-induced apoptosis in CD44-expressing 
colon cancer cells took place concurrently with alterations 
in caspase 9, caspase 3, Bcl-xL, and Bak (84). Recent studies 
have provided further evidence for the above notion. In CD44-
knockdown colon carcinoma cells, increased apoptosis was 
accompanied by both reductions in the levels of anti-apoptotic 
Bcl-2 and Bcl-xL expression and increases in the expression 
of pro-apoptotic Bax and cleaved caspase 3, caspase 8, and 
caspase 9 (85). In chronic lymphocytic leukemia cells exhibit-
ing high levels of cell surface CD44, the engagement of CD44 
by HA activated the PI3K/Akt and MAPK pathways to induce 
the expression of anti-apoptotic proteins and, in turn, promote 
survival (86).
In addition to HA–CD44 interactions, several survival/
anti-apoptotic mechanisms have been proposed for apoptosis 
resistance via CD44 variant isoforms. Binding of CD44v6 to 
HGF-initiated c-Met signaling that required association of 
the CD44 cytoplasmic tail with ezrin/radixin/moesin family 
members to regulate MEK and Erk signaling pathways (87). 
Moreover, CD44v6 promoted apoptosis resistance through 
FiGURe 3 | Hyaluronan and CD44 interactions regulate survival and 
multidrug resistance in cancer cells. (A) HA–CD44v3 interactions 
promote CSC signatures in human HNSCC through the formation of 
stem-cell-specific transcription factor complexes that include Oct4, Sox2, 
and Nanog. (B) A CD44 variant isoform (CD44v8–10) plays a role in 
stabilizing the glutamate–cystine transporter xCT, which promotes cystine 
uptake for GSH synthesis and leads to ROS suppression. (C) HA–CD44 
binding induces interaction of Nanog with Stat-3, which in turn stimulates 
Stat-3-dependent MDR1 gene expression. (D) The binding of HA to CD44 
promotes PKCϵ activity and causes Nanog phosphorylation. 
Phosphorylated Nanog then translocates from the cytosol to the nucleus 
and interacts with the microprocessor complex containing RNase III 
(DROSHA) and RNA helicase (p68) to produce the miR-21 required for 
up-regulation of MDR1.
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the assembly of ECM that triggered activation of PI3K/Akt 
and MAPK signaling cascades followed by inactivation of 
pro-apoptotic Bcl-2-associated death promoter (BAD) (88). 
Meanwhile, CD44v3 recruited the HB–EGF precursor and a 
proteolytically active form of matrilysin/MMP7 to the cell 
surface complex. The HB–EGF precursor was then cleaved by 
means of CD44-associated MMP7 and the resulting mature 
HB–EGF engaged and activated anti-apoptotic signals gener-
ated by ERBB4 RTK (89). The above findings point to CD44 
playing important roles in the survival of cancer cells and 
CSCs in both HA-dependent and HA-independent manners.
Drug and Stress Resistance induced by 
HA–CD44 interactions
Multidrug Resistance
Multidrug resistance in CSCs is a major obstacle for effective 
cancer therapy. CSC drug resistance can be partially attributed 
to the induction of survival/anti-apoptotic signals, as discussed 
above. Another hindrance to chemotherapy is rapid drug evacu-
ation from cancer cells mediated by multidrug transporters and 
MDR genes. Bourguignon et  al. demonstrated that HA–CD44 
interactions-induced association of Nanog and Stat-3 to stimulate 
Stat-3-dependent MDR1 gene expression. Upon HA binding, 
CD44 also enhanced ankyrin-regulated multidrug efflux (81). 
They further discovered a novel signaling pathway in which 
HA-CD44 interactions promoted activation of protein kinase 
Cϵ followed by Nanog phosphorylation and its nuclear trans-
location. This cascade eventually resulted in the up-regulation 
of MDR1 (90). HA–CD44 interactions not only induce MDR1 
expression but also up-regulate multidrug resistance protein 2 
in non-small cell lung cancer cells (91). Taken together, CD44 
figures prominently in the MDR of cancer cells and CSCs via HA 
binding (Figure 3).
Resistance to Oxidative Stress
Oxidative stress caused by an imbalance between reactive oxygen 
species (ROS) and antioxidants induces cell damage and death. 
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A metabolic switch from oxidative phosphorylation to glycolysis 
decreases mitochondrial oxygen consumption and ROS levels, 
and most cancer cells predominantly produce energy by glyco-
lysis, which reduces ROS production. Above all, CSCs effectively 
gain a survival/growth advantage by adapting their metabolism 
and maintaining cellular redox homeostasis, even under oxida-
tive stress conditions. Multiple mechanisms explaining how 
CD44 confers resistance to oxidative stress in CSCs have been 
proposed. For example, metabolic modulation by CD44 has 
been demonstrated to contribute to antioxidant status in cancer 
cells. Tamada et  al. found that CD44 interacted with pyruvate 
kinase M2 and enhanced glycolysis in p53-deficient or hypoxic 
cancer cells (92); CD44 knockdown then switched the metabolic 
flux from glycolysis to mitochondrial respiration and increased 
intracellular levels of ROS. CD44 also controls ROS defense by 
altering cellular glutathione (GSH) synthesis. Ishimoto et  al. 
described that a CD44 variant isoform (CD44v8–10) regulated 
redox status in cancer cells by stabilizing xCT, a glutamate–cys-
tine transporter (93) whose activity promotes cystine uptake for 
GSH synthesis (Figure 3). Other studies have shown that CD44-
positive cancer cells up-regulate antioxidant genes (93, 94). In 
one gastrointestinal cancer mouse model, CD44-positive gastric 
tumor cells expressed a set of antioxidant genes at higher levels 
as compared with CD44-negative tumor cells (93). Furthermore, 
CD44 can attenuate activation of the mammalian Hippo, c-Jun 
N-terminal kinase, and p53 signaling pathways, resulting in 
resistance to oxidative and cytotoxic agent-induced stress in 
glioblastoma multiforme cells (95). These findings suggest that 
CD44 can maintain low levels of ROS and orchestrate protective 
mechanisms against ROS-mediated damage. Thus, CSCs and 
other CD44-expressing cancer cells may reduce oxidative stress 
through a variety of mechanisms.
Resistance to Antitumor immunity
CD44-expressing cancer cells can acquire the capability to 
evade immune destruction. For instance, the interaction of 
CD44 with HA fragments led to immune escape of lung cancer 
cells from cytotoxic T lymphocyte-mediated cytotoxicity (96). 
In their study, Yasuda et  al. proposed a mechanism by which 
HA–CD44 interactions reduced the susceptibility of cancer 
cells to Fas/Fas ligand-mediated cytotoxicity by suppressing Fas 
expression. Moreover, the immunological properties of CD44-
positive cancer stem-like cells have been compared with those 
of CD44-negative cells in squamous cell carcinoma of the head 
and neck. Unlike CD44-negative cells, the CD44-positive cells 
strongly inhibited T-cell proliferation and efficiently induced 
regulatory T cells (Tregs) and myeloid-derived suppressor 
cells. Interestingly, a model for how HMW–HA may play an 
important role in the maintenance of immunological tolerance 
has been proposed as well. HMW-HA provided co-stimulatory 
signals by cross-linking with CD44 and modulated the function 
of Tregs via production of IL-2, IL-10, and TGF-β (97). IL-10 
production is a reported mechanism by which Tregs maintain 
immune tolerance (98). Tumor-derived HA fragments have also 
been shown to promote the development of immunosuppressive 
M2 macrophages by dynamically educating recruited blood 
monocytes (99). Our recent study demonstrated the preferential 
engagement of immunosuppressive M2 macrophages in an 
HA-rich stromal microenvironment (47). The presence of a large 
pericellular HA coat likely impaired immune surveillance due to 
steric hindrance. Taken together, CSCs have a higher malignant 
potential due to numerous escape mechanisms from immune 
attack that will necessitate the development of novel strategies 
to overcome.
Conclusion
This review emphasizes the diverse roles of HA and its CD44 
receptor on the stemness and survival of CSCs. Recent studies 
have enabled us to postulate reliable mechanisms by which HA 
functions in the regulation of CSC maintenance that may be 
partly dependent on the mesenchymal conversion of cancer cells. 
Growing evidence also indicates that CD44 is not only a common 
marker of CSCs but also plays a dominant role in maintaining 
their stemness. HA and CD44 enhance cell survival and confer 
resistance to chemotherapy and oxidative stress in CSCs as well.
Intense efforts are currently being directed toward the devel-
opment of therapeutic strategies that selectively target CSCs. A 
more complete understanding of the mechanisms controlling 
how HA and CD44 mediate the stemness of CSCs will aid in 
the development of new treatment strategies to improve the 
outcome of cancer patients.
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